Your body changed.Your plan should too.

Some lean mass loss is common, and the amount varies considerably. A systematic review of six semaglutide trials covering 1,541 patients found reductions ranging from almost none to roughly 40% of total weight lost, with larger trials reporting the more notable figures. A network meta-analysis across the drug class puts it around a quarter of total loss on average. Encouragingly, fat loss is usually greater and lean mass as a proportion of body weight often improves. The outcome is influenced by what surrounds the medication: protein intake, resistance loading, and hormonal status. Those are exactly what your program supplies. The review is at PubMed.

That is a common and legitimate reason to be here, and it is often a hormonal question rather than a caloric one. The same number on the scale distributed differently, more centrally and with less lean tissue, points at testosterone, estradiol, thyroid, or insulin handling. In that situation your program focuses on the hormonal side. See HRT & TRT for where that conversation usually goes.

Much of the older confusion traces to a single large study from the early 2000s whose findings were widely generalized beyond the population studied. Current published position guidance is considerably more nuanced. For women under sixty or within ten years of menopause onset, without contraindications, the benefit-risk balance is described as favorable for vasomotor symptoms and for maintaining bone density. Beyond that window it is described as less favorable because absolute risks rise. Risk also varies by type, dose, duration, route, and whether a progestogen is used. That is why guidance calls explicitly for individualized, shared decision-making, which is exactly how your program is run. The 2022 position statement is at PubMed.

Normal range describes where most people your age and sex fall. It is a population statistic, not an individual target. Someone sitting at the bottom of a range can have meaningfully different energy, clarity, and recovery than the same person in the upper third. There is also the question of what was measured. A hormonal workup that captured TSH but not free T3, free T4, and reverse T3 has left out part of the thyroid picture. The question this program asks is not whether you are in range. It is where in that range you actually function.

Your program plans for it from the start. Appetite returns after discontinuation, and weight regain is well documented, especially when lean mass was lost along the way. That is why your program addresses the underlying hormonal environment and protects lean tissue throughout, giving you the strongest foundation for maintaining your progress.

Valere operates as a private-pay practice. Coverage for GLP-1 medications through commercial insurance varies considerably and is worth checking with your carrier separately. The program itself, meaning the panel, time with your care team, body composition tracking, and coaching, is private-pay, which is what allows it to be built around what your results show. Payment plans and membership options are available.